On the basis of therapeutic application, the injectable
drug delivery market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other diseases.
Injectable Drug Delivery Market, 2020 - Becton, Dickinson and Company, Baxter, Gerresheimer, Pfizer,, Schott, Sandoz, Teva, and Eli Lilly Dominate the $574 Billion Industry
The global injectable
drug delivery market has been segmented based on indication, formulations, device type and geography.
drug product demand by indication and therapy to 2018
At baseline, women were classified according to whether they chose to initiate the injectable
, oral contraceptives or no hormonal method.
Trends in injectable
drug delivery dealmaking in the biopharma industry since 2010
Specialty Drug Market Dynamics - Injectable
Drug Demand Drivers - Drug Development Factors - Market Factors - Technology Factors - Self-Injection Product Design Factors - Ease-of-Use - Safety and Simplicity - Patient Interface - Competitive Landscape - Risks and Opportunities
Reviews the design of injectable
biomaterials as well as their rheological properties and the mechanical properties of injectable
polymers and composites
TechNavio's report, Global Facial Injectable
Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts.
Drug Delivery Partnering 2010-2015 report provides understanding and access to the injectable
drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.
Drug Ecosystem Injectable
Drug Demand Drivers Drug Development Factors Market Factors Technology Factors Competitive Landscape Autoinjectors Needle-free Injectors Pen Injectors Prefilled Syringes Safety Syringes Risks and Opportunities
Alkermes currently has two commercial products: RISPERDAL([R]) CONSTA([R]) [(risperidone) long-acting injection], the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL([R]) (naltrexone for extended-release injectable
suspension) the first and only once-monthly injectable
medication approved for the treatment of alcohol dependence and marketed in the U.
com/research/d8qj9s/european) has announced the addition of the "European Injectable
Drug Delivery - Market Forecasts to 2017" report to their offering.